NOVAST LABS
GenericsNOVAST LABS is a generic drug manufacturer focused on Dermatology, Cardiovascular, Neurology.
NOVAST LABS's Key Drugs
NOVAST LABS's core commercial portfolio centers on CONJUGATED ESTROGENS, YAELA, MELAMISA, spanning Dermatology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Vasomotor Symptoms
Premenstrual Dysphoric Disorder
Premenstrual Dysphoric Disorder
Premenstrual Dysphoric Disorder
Pregnancy
NOVAST LABS's Recent FDA Approvals
New NDA/BLA approvals for NOVAST LABS over the last two years — novel drugs only, excluding generics and label supplements.
NOVAST LABS's Therapeutic Areas
NOVAST LABS's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NOVAST LABS's Top Competitors
NOVAST LABS's closest competitors by therapeutic-area and drug-target overlap include Bayer, Pfizer, and OTSUKA. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NOVAST LABS Pipeline Snapshot
Active clinical trials for NOVAST LABS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CONJUGATED ESTROGENS leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (25)
Discontinued (0)
Company Info
- First Approval
- 2010-12-29
- Latest
- 2026-08-11
- Applications
- 53